Calamos Advisors LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2020$2,207,000
-54.6%
2,500,000
-50.0%
0.01%
-58.8%
Q2 2020$4,859,000
-0.4%
5,000,0000.0%0.03%
-10.5%
Q1 2020$4,879,000
-6.3%
5,000,0000.0%0.04%
+46.2%
Q4 2019$5,205,000
+12.5%
5,000,0000.0%0.03%
+4.0%
Q3 2019$4,628,000
+6.7%
5,000,0000.0%0.02%
+4.2%
Q2 2019$4,337,000
-10.7%
5,000,0000.0%0.02%
-20.0%
Q1 2019$4,855,000
-5.9%
5,000,0000.0%0.03%
-11.8%
Q4 2018$5,157,000
-13.6%
5,000,0000.0%0.03%
+3.0%
Q3 2018$5,972,000
+20.3%
5,000,0000.0%0.03%
+10.0%
Q2 2018$4,966,0005,000,0000.03%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
LINDEN ADVISORS LP 71,957,000$88,374,0003.14%
Context Capital Management, LLC 3,500,000$4,288,0002.87%
Mohican Financial Management, LLC 1,000,000$1,250,0002.40%
Verition Fund Management LLC 8,000,000$9,835,0000.79%
ZAZOVE ASSOCIATES LLC 8,170,000$10,024,0000.51%
Baupost Group 30,000,000$37,125,0000.46%
WOLVERINE ASSET MANAGEMENT LLC 24,020,000$29,431,0000.33%
SSI INVESTMENT MANAGEMENT LLC 3,007,000$3,683,0000.31%
CSS LLC/IL 2,900,000$3,556,0000.17%
Rock Springs Capital Management LP 1,500,000$1,844,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders